Cary-based Veloxis Pharmaceuticals injects $60M debt financing for transplant tech
CARY — Veloxis Pharmaceuticals A/S (OMX: VELO), a specialty pharmaceutical company focused on organ transplant technology, has received $60 million in debt financing from Athyrium Capital Management, a healthcare investment firm. The financing is in the form of a five-year, floating rate, interest only note. Veloxis Pharmaceuticals A/S is...
Read More
